TRIB (Trinity Biotech plc) Market Value to Book Value Ratio

Trinity Biotech plc (TRIB) develops diagnostic systems for detecting diabetes and infections, competing through a closed ecosystem of equipment and high-cost consumables. The company generates revenue by supplying portable analyzers and reagents to global clinics. Current price action, reaching -0.07, confirms the business's resilience due to its leadership in the glucose testing segment and the optimization of internal costs amid moderate growth.

TRIB - trinitybiotech.com Market-to-Book Ratio over the range 07/04/2022 - 10/26/2026

Financial and market metric breakdowns for Trinity Biotech plc (TRIB)

- price and consensus price forecast:

Stock Price trinitybiotech.com|TRIB - Price Target Chart

- market capitalization data:

Market Value Trinity Biotech Corp|TRIB - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share Trinity Biotech|TRIB - Total Stockholders' Equity|Market Capitalization to Book Value Ratio trinitybiotech.com|TRIB - Total Business Assets

- debt and liquidity data:

Total Debt to Capital Trinity Biotech plc|TRIB - Long-Term Debt to Capital|Short-Term Debt to Equity trinitybiotech.com|TRIB - Company Aggregate Debt|Debts to Book Capitalization Trinity Biotech Corp

Initial company analysis:Trinity Biotech PLC - TRIB

Flagship merchandise of trinitybiotech.com

Trinity Biotech plc (TRIB) provides critical HIV and diabetes diagnostics through a global network of laboratories. This price-to-book ratio measures the market price premium over net assets. The metric captures the business's fundamental foundation, filtering out short-term speculative fluctuations. For the defensive healthcare sector, the chart's stable trajectory confirms capitalization resilience. Investors should view this indicator as a measure of price strength during periods of market volatility.

Direct competitors